Breaking News Instant updates and real-time market news.

MDXG

MiMedx

$8.83

-0.03 (-0.34%)

08:52
10/10/16
10/10
08:52
10/10/16
08:52

MiMedx reports Q3 revenue $64.4M, consensus $63.12M

Parker "Pete" Petit, Chairman and CEO stated, "We are very pleased that we were able to exceed our third quarter revenue guidance. This makes 20 consecutive quarters of sequential revenue growth and 19 of 20 quarters of meeting or exceeding our revenue guidance. Our core advanced wound care revenues were led by our commercial accounts. With the launch of our two new product lines in the third quarter, AmnioFill and OrthoFlo Lyophilized, we are looking forward to very robust growth in the fourth quarter and beyond. Third quarter revenue is typically impacted by vacations, and we are pleased with our third quarter results in light of that fact. With many year-end deductibles being met during the fourth quarter, we anticipate that typical additive impact on our fourth quarter revenue."

  • 09

    Nov

  • 10

    Nov

MDXG MiMedx
$8.83

-0.03 (-0.34%)

05/17/16
PIPR
05/17/16
NO CHANGE
Target $12
PIPR
Overweight
Osiris false claims lawsuit another overhang, says Piper Jaffray
After MiMedx (MDXG) announced that it has filed suit against Osiris (OSIR), asserting that Osiris "knowingly and willfully made false and misleading representations," Piper Jaffray analyst Edward Tenthoff said it is unclear at this time what merit the claims have, but added that the lawsuit represents "yet another" overhang for Osiris shares. Noting that he expects BioSurgery sales to return Osiris to profitability, Tenthoff maintains an Overweight rating and $12 price target on the stock.
06/29/16
BMUR
06/29/16
NO CHANGE
Target $12
BMUR
Buy
MiMedx expects second half acceleration, says Brean Capital
Brean Capital said MiMedx continues to be confident in Q2 but expects a second half acceleration with surgical uptake the key opportunity. The firm's doctor checks suggest growing interest in using amniotic tissue for tendon repair procedures along with GI surgeons showing interest as well. Brean Capital reiterated its Buy rating and $12 price target on MiMedx shares.
07/27/16
BMUR
07/27/16
NO CHANGE
Target $12
BMUR
Buy
MiMedx shares remain undervalued, says Brean Capital
Brean Capital believes Mimedx shares remain undervalued following Q2 earnings. The firm said higher spending cutting into its earnings was a disappointment but at this stage in the company's development they noted the focus is on top-line growth, which remains healthy. Brean Capital reiterated its Buy rating and $12 price target on MiMedx shares.
08/31/16
BMUR
08/31/16
NO CHANGE
Target $12
BMUR
Buy
MiMedx Epifix trial news removes major overhang, says Brean Capital
Brean Capital analyst Jason Wittes said the surprise announcement that MiMedx is close to completing DFU and VLU trials for Epifix ahead of the September FDA hearing to discuss the regulator's guidance on human cells, tissues, and cellular and tissue based products removes a major overhang for the stock. The analyst felt most investors assumed the company was not positioned to immediately address the potential for increased regulatory requirements given their strong stance against up-regulation. Wittes reiterated his Buy rating and $12 price target on MiMedx shares.

TODAY'S FREE FLY STORIES

AGIO

Agios Pharmaceuticals

$70.33

1.53 (2.22%)

08:59
01/18/18
01/18
08:59
01/18/18
08:59
Recommendations
Agios Pharmaceuticals analyst commentary  »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 19

    Jan

PRTK

Paratek Pharmaceuticals

$17.68

-0.075 (-0.42%)

08:59
01/18/18
01/18
08:59
01/18/18
08:59
Syndicate
Paratek Pharmaceuticals 3.11M share Spot Secondary priced at $16.10 »

BTIG acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ALXN

Alexion

$122.12

-2.36 (-1.90%)

08:59
01/18/18
01/18
08:59
01/18/18
08:59
Initiation
Alexion initiated  »

Alexion assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTZ

MasTec

$51.90

0.75 (1.47%)

08:59
01/18/18
01/18
08:59
01/18/18
08:59
Recommendations
MasTec analyst commentary  »

MasTec price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$57.18

0.25 (0.44%)

08:57
01/18/18
01/18
08:57
01/18/18
08:57
Downgrade
Continental Resources rating change  »

Continental Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GATX

GATX

$65.21

-0.5 (-0.76%)

08:57
01/18/18
01/18
08:57
01/18/18
08:57
Earnings
GATX reports Q4 non-GAAP EPS 68c, consensus 73c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

XLRN

Acceleron

$44.99

-0.03 (-0.07%)

08:57
01/18/18
01/18
08:57
01/18/18
08:57
Initiation
Acceleron initiated  »

Acceleron assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$231.37

2.83 (1.24%)

08:56
01/18/18
01/18
08:56
01/18/18
08:56
Hot Stocks
Becton Dickinson says enrollment complete in Lutonix below-the-knee trial »

BD announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

SCHW

Charles Schwab

$56.09

0.56 (1.01%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Recommendations
Charles Schwab analyst commentary  »

Charles Schwab price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$31.18

-0.06 (-0.19%)

, GE

General Electric

$17.35

-0.86 (-4.72%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Options
Notable open interest changes for January 18th »

Wednesday's total…

BAC

Bank of America

$31.18

-0.06 (-0.19%)

GE

General Electric

$17.35

-0.86 (-4.72%)

FB

Facebook

$177.60

-0.79 (-0.44%)

BABA

Alibaba

$183.83

1.43 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 23

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 07

    Feb

  • 15

    Feb

  • 28

    Feb

08:55
01/18/18
01/18
08:55
01/18/18
08:55
General news
U.S. housing starts dropped 8.2% to 1.192 M in December »

U.S. housing starts…

ABM

ABM

$38.73

0.26 (0.68%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Conference/Events
ABM to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AMGP

Antero Midstream GP

$20.89

-0.11 (-0.52%)

, AM

Antero Midstream Partners

$30.95

-0.8 (-2.52%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Conference/Events
Antero Resources to host analyst day »

Analyst Day to be held in…

AMGP

Antero Midstream GP

$20.89

-0.11 (-0.52%)

AM

Antero Midstream Partners

$30.95

-0.8 (-2.52%)

AR

Antero Resources

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

BIVV

Bioverativ

$62.32

-1.55 (-2.43%)

08:54
01/18/18
01/18
08:54
01/18/18
08:54
Initiation
Bioverativ initiated  »

Bioverativ assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 25

    Apr

UTHR

United Therapeutics

$140.32

5.2 (3.85%)

08:54
01/18/18
01/18
08:54
01/18/18
08:54
Initiation
United Therapeutics initiated  »

United Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$82.47

2.05 (2.55%)

08:53
01/18/18
01/18
08:53
01/18/18
08:53
Recommendations
PayPal analyst commentary  »

PayPal Q4 may see upside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

EDGE

Edge Therapeutics

08:52
01/18/18
01/18
08:52
01/18/18
08:52
Initiation
Edge Therapeutics initiated  »

Edge Therapeutics assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$90.14

1.79 (2.03%)

08:52
01/18/18
01/18
08:52
01/18/18
08:52
Recommendations
Microsoft analyst commentary  »

Microsoft price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 31

    Jan

  • 07

    Feb

SNAP

Snap

$13.52

0.02 (0.15%)

, FB

Facebook

$177.60

-0.79 (-0.44%)

08:52
01/18/18
01/18
08:52
01/18/18
08:52
Conference/Events
SunTrust Internet & digital media analyst holds analyst/industry conference call »

Internet & Digital…

SNAP

Snap

$13.52

0.02 (0.15%)

FB

Facebook

$177.60

-0.79 (-0.44%)

GOOG

Alphabet

$1,131.98

10.22 (0.91%)

GOOGL

Alphabet Class A

$1,139.10

8.4 (0.74%)

TWTR

Twitter

$24.56

-0.1 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

  • 18

    Mar

BMRN

BioMarin

$89.64

-0.6 (-0.66%)

08:52
01/18/18
01/18
08:52
01/18/18
08:52
Initiation
BioMarin initiated  »

BioMarin assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 25

    May

LEN

Lennar

$70.71

1.93 (2.81%)

08:51
01/18/18
01/18
08:51
01/18/18
08:51
Upgrade
Lennar rating change  »

Lennar upgraded to Buy at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICBK

County Bancorp

$30.73

-1.57 (-4.86%)

08:51
01/18/18
01/18
08:51
01/18/18
08:51
Earnings
County Bancorp reports Q4 EPS 30c, consensus 47c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHM

PulteGroup

$34.40

0.64 (1.90%)

08:51
01/18/18
01/18
08:51
01/18/18
08:51
Upgrade
PulteGroup rating change  »

PulteGroup upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

AVXS

AveXis

$104.87

-0.14 (-0.13%)

08:50
01/18/18
01/18
08:50
01/18/18
08:50
Initiation
AveXis initiated  »

AveXis initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

MS

Morgan Stanley

$55.35

0.75 (1.37%)

08:50
01/18/18
01/18
08:50
01/18/18
08:50
Hot Stocks
Morgan Stanley CEO sees immediate positive impact from tax reform »

Sees meaningful reduction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.